155 related articles for article (PubMed ID: 923614)
1. Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.
Hedley DW; McElwain TJ; Currie GA
Eur J Cancer (1965); 1977 Oct; 13(10):1169-73. PubMed ID: 923614
[No Abstract] [Full Text] [Related]
2. Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.
Newlands ES; Oon CJ; Roberts JT; Elliott P; Mould RF; Topham C; Madden FJ; Newton KA; Westbury G
Br J Cancer; 1976 Aug; 34(2):174-9. PubMed ID: 962994
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
[TBL] [Abstract][Full Text] [Related]
4. Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma (Trial 6): preliminary report.
Veronesi U; Beretta G
Recent Results Cancer Res; 1978; 68():375-9. PubMed ID: 752873
[No Abstract] [Full Text] [Related]
5. Adjuvant therapy in malignant melanoma: a trial of immunotherapy. chemotherapy, and combined treatment.
Kaufman SD; Cosimi AB; Wood WC; Carey RW
Recent Results Cancer Res; 1978; 68():380-6. PubMed ID: 752874
[No Abstract] [Full Text] [Related]
6. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
Wood WC; Cosimi AB; Carey RW; Kaufman SD
Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
[TBL] [Abstract][Full Text] [Related]
7. Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
Ramseur WL; Richards F; Muss HB; Rhyne L; Cooper MR; White DR; Stuart JJ; Spurr CL
Cancer Treat Rep; 1978 Jul; 62(7):1085-7. PubMed ID: 356970
[TBL] [Abstract][Full Text] [Related]
8. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
9. Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
Currie GA; McElwain TJ
Br J Cancer; 1975 Feb; 31(2):143-56. PubMed ID: 1164466
[TBL] [Abstract][Full Text] [Related]
10. Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.
Peter HH; Deutschmann KE; Deinhardt J; Deicher H
Recent Results Cancer Res; 1978; 68():367-74. PubMed ID: 752872
[No Abstract] [Full Text] [Related]
11. Letter: Chemoimmunotherapy of malignant melanoma.
N Engl J Med; 1975 Jan; 292(3):159-60. PubMed ID: 1196343
[No Abstract] [Full Text] [Related]
12. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
[TBL] [Abstract][Full Text] [Related]
13. Chemoimmunotherapy in disseminated melanoma and colorectal carcinoma.
Gough IR; Bolton PM; Clunie GJ; Burnett W
Aust N Z J Surg; 1978 Jun; 48(3):296-300. PubMed ID: 281221
[TBL] [Abstract][Full Text] [Related]
14. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
[TBL] [Abstract][Full Text] [Related]
15. The survival of patients with malignant melanoma receiving BCG with or without chemotherapy.
Green MD; MacKay IR; Buckley JC; Coates AS
Aust N Z J Surg; 1979 Jun; 49(3):335-9. PubMed ID: 289374
[TBL] [Abstract][Full Text] [Related]
16. Mumps virus and BCG vaccine in metastatic melanoma.
Minton JP
Arch Surg; 1973 Apr; 106(4):503-6. PubMed ID: 4572347
[No Abstract] [Full Text] [Related]
17. The role of immunotherapy in the management of patients with malignant melanoma.
Goodnight JE; Morton DL
World J Surg; 1979 Jul; 3(3):309-20. PubMed ID: 382645
[No Abstract] [Full Text] [Related]
18. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of malignant melanoma.
Thiers BH
J Am Acad Dermatol; 1982 Apr; 6(4 Pt 1):559-62. PubMed ID: 6176602
[No Abstract] [Full Text] [Related]
20. Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.
Mitchell MS; Mokyr MB; Davis JM
J Clin Invest; 1977 Jun; 59(6):1017-26. PubMed ID: 863999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
